(Updated for KEI’s corrected brief). On Wednesday December 16, 2020, Knowledge Ecology International (KEI) filed an amicus curiae brief in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. (“GSK”, “Teva”). The case concerns secondary indications of medicines, and whether Teva induced… Continue Reading
On August 13, 2014, the Republic of South Africa (RSA) Competition Commission (CC) released the redacted versions of the reports provided to the CC by CPTech in 2003 in the TAC competition case involving GSK and Boehringer Ingelheim. A complete… Continue Reading
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading
September 3, 2011 From KEI staff review of Wikileaks cables (/wikileaks) On May 14, 2008, The US Embassy in Warsaw sent a cable that discussed additions to the list of pharmaceutical products reimbursed by the government. A few highlights from… Continue Reading